Literature DB >> 33506938

Procalcitonin and sepsis in the Emergency Department: an update.

D Velissaris1, N Zareifopoulos, M Lagadinou, C Platanaki, K Tsiotsios, E L Stavridis, D I Kasartzian, C Pierrakos, V Karamouzos.   

Abstract

OBJECTIVE: Due to significant mortality and morbidity which may be reduced by prompts treatment, there is great interest in determining an ideal biomarker for the diagnosis of sepsis upon presentation to the Emergency Department. The most specific test is a positive blood culture, but its sensitivity is very low, and the results are usually available 2 days after sampling. For this reason, research is conducted into serum biomarkers with greater sensitivity for which results can be available within hours of presentation. High initial procalcitonin levels are a sensitive marker of bacterial infection, and the degree of procalcitonin elevation may determine which patients are at greater risk for adverse outcomes (mortality or ICU admission). The purpose of this narrative review is to evaluate the utility of procalcitonin as a diagnostic marker of sepsis in the emergency department and the use of procalcitonin-guided management algorithms.
MATERIALS AND METHODS: A PubMed search was conducted in June 2020 for procalcitonin, resulting in the retrieval of 371 articles which were screened for relevance. 48 articles were included in the review.
CONCLUSIONS: Procalcitonin elevation may be used as an indication for initiation of antibiotic treatment, and antibiotics may be discontinued once procalcitonin normalizes. This approach leads to reduced antibiotic consumption, but it is not yet clear whether it ensures better outcomes for patients. Procalcitonin in centers where it is available could be a useful diagnostic and prognostic biomarker for patients presenting to the Emergency Department with symptoms suggestive of sepsis. Further research is however required to determine whether the use of procalcitonin measurements in management algorithms leads to improved patient outcomes.

Entities:  

Year:  2021        PMID: 33506938     DOI: 10.26355/eurrev_202101_24416

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

1.  Effect of procalcitonin on the severity and prognostic value of elderly patients with a severe infection of oral and maxillofacial space.

Authors:  Xin-Yan Lin; Yu-Zhao Lin; Shao-Hua Lin; Jun-Jie Lian
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817

2.  Procalcitonin-guided antibiotic therapy for pediatrics with infective disease: A updated meta-analyses and trial sequential analysis.

Authors:  Peng Li; JiaLe Liu; Junjun Liu
Journal:  Front Cell Infect Microbiol       Date:  2022-09-21       Impact factor: 6.073

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.